Document Classification

Section Type: RESULTS

Text: sICAM-1 levels in the trial group were significantly lower at weeks 6 and 12 (373. 64 + / -89. 33 versus 459. 53 + / -123. 59 and 447. 83 + / -111. 21 versus 513. 91 + / -150. 46, both P < 0. 01), and plasma TGF-beta1 levels were lower at week 3 and 6 (5. 43 + / -1. 47 versus 6. 22 + / -1. 78 and 5. 93 + / -2. 39 versus 7. 67 + / -2. 74, P < 0. 05 and 0. 01, respectively) in comparison with the control group.